Wall Street brokerages expect Axovant Sciences Ltd. (NYSE:AXON) to announce ($0.58) earnings per share for the current quarter, Zacks reports. Zero analysts have made estimates for Axovant Sciences’ earnings, with the lowest EPS estimate coming in at ($0.65) and the highest estimate coming in at ($0.55). Axovant Sciences reported earnings of ($0.39) per share during the same quarter last year, which indicates a negative year-over-year growth rate of 48.7%. The business is expected to announce its next quarterly earnings report on Monday, November 6th.

On average, analysts expect that Axovant Sciences will report full-year earnings of ($2.32) per share for the current year, with EPS estimates ranging from ($2.71) to ($1.77). For the next financial year, analysts forecast that the firm will report earnings of ($3.01) per share, with EPS estimates ranging from ($4.21) to ($1.92). Zacks’ EPS averages are an average based on a survey of sell-side research analysts that follow Axovant Sciences.

Axovant Sciences (NYSE:AXON) last released its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.53) by $0.12.

A number of analysts have issued reports on AXON shares. Cowen and Company reiterated an “outperform” rating and issued a $30.00 target price on shares of Axovant Sciences in a research note on Wednesday, June 21st. Jefferies Group LLC started coverage on shares of Axovant Sciences in a research note on Monday, July 10th. They issued a “buy” rating and a $40.00 target price for the company. BidaskClub cut shares of Axovant Sciences from a “hold” rating to a “sell” rating in a research note on Saturday. Zacks Investment Research cut shares of Axovant Sciences from a “hold” rating to a “sell” rating in a research note on Tuesday, July 11th. Finally, CIBC lifted their target price on shares of Axovant Sciences from $26.00 to $30.00 and gave the company an “outperform” rating in a research note on Wednesday, June 14th. Three analysts have rated the stock with a sell rating and nine have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $27.75.

Axovant Sciences (AXON) traded down 2.52% during midday trading on Monday, hitting $20.48. 270,681 shares of the stock traded hands. The firm’s market cap is $2.20 billion. Axovant Sciences has a 1-year low of $11.01 and a 1-year high of $26.49. The company has a 50-day moving average price of $22.68 and a 200-day moving average price of $19.46.

COPYRIGHT VIOLATION NOTICE: “Zacks: Analysts Expect Axovant Sciences Ltd. (AXON) to Announce -$0.58 EPS” was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international copyright law. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/08/21/zacks-analysts-expect-axovant-sciences-ltd-axon-to-announce-0-58-eps.html.

Several institutional investors have recently added to or reduced their stakes in the stock. Bank of America Corp DE raised its position in Axovant Sciences by 38.9% in the first quarter. Bank of America Corp DE now owns 7,396 shares of the biotechnology company’s stock worth $111,000 after buying an additional 2,072 shares in the last quarter. Oppenheimer & Co. Inc. purchased a new position in Axovant Sciences during the first quarter worth approximately $219,000. Primecap Management Co. CA raised its position in Axovant Sciences by 300.1% in the first quarter. Primecap Management Co. CA now owns 2,878,930 shares of the biotechnology company’s stock worth $43,011,000 after buying an additional 2,159,428 shares in the last quarter. American International Group Inc. raised its position in Axovant Sciences by 7.1% in the first quarter. American International Group Inc. now owns 15,052 shares of the biotechnology company’s stock worth $225,000 after buying an additional 998 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its position in Axovant Sciences by 4.1% in the first quarter. JPMorgan Chase & Co. now owns 489,024 shares of the biotechnology company’s stock worth $7,306,000 after buying an additional 19,129 shares in the last quarter. 94.54% of the stock is currently owned by institutional investors.

Axovant Sciences Company Profile

Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.

Get a free copy of the Zacks research report on Axovant Sciences (AXON)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Axovant Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.